

Hemcheck Sweden AB (publ)
556811-5272
2018-01-11 09.00



PRESS RELEASE

HEM CHECK SIGNS AGREEMENT WITH GLOBAL SHL GROUP

HemCheck has signed a long-term agreement with SHL Technologies Limited, a subsidiary of the international SHL Group. The agreement entails SHL will manufacture the disposable tests that are used in HemCheck's product concept, Helge, for point of care hemolysis detection. HemCheck's goal is to CE-mark and launch Helge on the Swedish market during 2018.

- We are very pleased to sign a long-term agreement with SHL. SHL is a competent partner, both in terms of handling large volumes and small batches, which is of great importance for us during the launch phase that HemCheck will soon enter, says CEO Annelie Brolinson.
- HemCheck has a unique product that will be able to contribute to improving patient flows with large cost savings as a result, in Sweden and globally. We look forward to continued cooperation, says Gabor Papp, SHL Technologies.
- SHL has vast global experience, which can aid us in further international expansion. In addition, SHL Group is, since spring 2017, one of the largest shareholders in HemCheck AB. That they have chosen to enter into this agreement with us demonstrates that they believe in our business idea and want to be an active business partner from the early launch phase, continues Annelie Brolinson.

For further information, contact:

Hemcheck Sweden AB (publ)
Annelie Brolinson, CEO
Phone: +46 70 288 0826
E-mail: annelie.brolinson@hemcheck.com

About HemCheck

HemCheck Sweden AB (publ.) is developing and commercializing a novel product concept (Helge) that detects hemolysis in blood samples at the point of care. Hemolysis, or the rupturing of red blood cells, is the most common reason for blood samples to be deemed unfit for laboratory analysis. When a blood sample cannot be analyzed, it results in delayed treatment entailing increased risks for patients and higher costs for clinics. HemCheck offers a solution to this global problem by providing a fast and reliable test that makes every sample count. HemCheck Sweden AB (publ.) is a privately held medical technology company based in Karlstad, Sweden.

About SHL Group

SHL Group designs, develops and manufactures medical technology products, mainly advanced drug delivery devices such as auto injectors, pen injectors and inhalers. With locations in Taiwan, Sweden, China and the US, SHL Group is the world's leading supplier of auto injectors. Among their customers are the world's largest pharmaceutical and biotechnology companies. SHL Group was established in 1989 and today has more than 3,700 employees.

Important information

This is information which HemCheck is required to disclose according to EU Market Abuse Regulation law. The information was provided by the above contact person's auspices, for publication on January 11, 2018, at 09:00.